Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Inflammatory Bowel Diseases

  Free Subscription

Articles published in Gut

Retrieve available abstracts of 124 articles:
HTML format

Single Articles

    July 2022
  1. XIONG S, Whitehurst CE, Li L, Heo GS, et al
    Reverse translation approach generates a signature of penetrating fibrosis in Crohn's disease that is associated with anti-TNF response.
    Gut. 2022;71:1289-1301.
    PubMed     Abstract available

    June 2022
  2. DANESE S, Solitano V, Jairath V, Peyrin-Biroulet L, et al
    The future of drug development for inflammatory bowel disease: the need to ACT (advanced combination treatment).
    Gut. 2022 Jun 14. pii: gutjnl-2022-327025. doi: 10.1136/gutjnl-2022-327025.

  3. WONG ECL, Dulai PS, Narula N
    Correspondence on "PICaSSO Histologic Remission Index (PHRI) in ulcerative colitis: development of a novel simplified histological score for monitoring mucosal healing and predicting clinical outcomes and its applicability in an artificial intelligenc
    Gut. 2022 Jun 7. pii: gutjnl-2022-327661. doi: 10.1136/gutjnl-2022-327661.

  4. STIDHAM RW, Vickers A, Singh K, Waljee AK, et al
    From clinical trials to clinical practice: how should we design and evaluate prediction models in the care of IBD?
    Gut. 2022;71:1046-1047.

  5. KAPLAN GG, Ma C, Charlton C, Kanji JN, et al
    Antibody response to SARS-CoV-2 among individuals with IBD diminishes over time: a serosurveillance cohort study.
    Gut. 2022;71:1229-1231.

  6. NARULA N, Wong ECL, Colombel JF, Sandborn WJ, et al
    Predicting endoscopic remission in Crohn's disease by the modified multiplier SES-CD (MM-SES-CD).
    Gut. 2022;71:1078-1087.
    PubMed     Abstract available

    May 2022
  7. QUAN J, Ma C, Panaccione R, Hracs L, et al
    Serological responses to three doses of SARS-CoV-2 vaccination in inflammatory bowel disease.
    Gut. 2022 May 23. pii: gutjnl-2022-327440. doi: 10.1136/gutjnl-2022-327440.

    April 2022
  8. LIN S, Lau LH, Chanchlani N, Kennedy NA, et al
    Recent advances in clinical practice: management of inflammatory bowel disease during the COVID-19 pandemic.
    Gut. 2022 Apr 27. pii: gutjnl-2021-326784. doi: 10.1136/gutjnl-2021-326784.
    PubMed     Abstract available

  9. VOSKENS C, Stoica D, Rosenberg M, Vitali F, et al
    Autologous regulatory T-cell transfer in refractory ulcerative colitis with concomitant primary sclerosing cholangitis.
    Gut. 2022 Apr 15. pii: gutjnl-2022-327075. doi: 10.1136/gutjnl-2022-327075.
    PubMed     Abstract available

  10. JESS T, Vestergaard MV, Iversen AT, Allin KH, et al
    Undiagnosed inflammatory bowel disease among individuals undergoing colorectal cancer screening: a nationwide Danish cohort study 2014-2018.
    Gut. 2022 Apr 12. pii: gutjnl-2022-327296. doi: 10.1136/gutjnl-2022-327296.

  11. RAINE T, Pavey H, Qian W, Moran GW, et al
    Establishment of a validated central reading system for ileocolonoscopy in an academic setting.
    Gut. 2022;71:661-664.

  12. JIMENEZ-VARGAS NN, Yu Y, Jensen DD, Bok DD, et al
    Agonist that activates the micro-opioid receptor in acidified microenvironments inhibits colitis pain without side effects.
    Gut. 2022;71:695-704.
    PubMed     Abstract available

    March 2022
  13. GORDON IO, Bettenworth D, Bokemeyer A, Srivastava A, et al
    International consensus to standardise histopathological scoring for small bowel strictures in Crohn's disease.
    Gut. 2022;71:479-486.
    PubMed     Abstract available

  14. PAGANO E, Elias JE, Schneditz G, Saveljeva S, et al
    Activation of the GPR35 pathway drives angiogenesis in the tumour microenvironment.
    Gut. 2022;71:509-520.
    PubMed     Abstract available

    February 2022
  15. GUI X, Bazarova A, Del Amor R, Vieth M, et al
    PICaSSO Histologic Remission Index (PHRI) in ulcerative colitis: development of a novel simplified histological score for monitoring mucosal healing and predicting clinical outcomes and its applicability in an artificial intelligence system.
    Gut. 2022 Feb 16. pii: gutjnl-2021-326376. doi: 10.1136/gutjnl-2021-326376.
    PubMed     Abstract available

  16. LI X, Tong X, Wong ICK, Peng K, et al
    Lack of inflammatory bowel disease flare-up following two-dose BNT162b2 vaccine: a population-based cohort study.
    Gut. 2022 Feb 8. pii: gutjnl-2021-326860. doi: 10.1136/gutjnl-2021-326860.

  17. MA C, Khanna R, Guizzetti L, Zou G, et al
    Methods for handling missing segments in Crohn's disease clinical trials: analysis from the EXTEND trial.
    Gut. 2022;71:447-448.

  18. LIU Z, Liu X, Liang J, Shi Y, et al
    Unusual cause of bloody stool with earache and saddle-nose deformity.
    Gut. 2022;71:264-356.

    January 2022
  19. SPALINGER MR, Shawki A, Chatterjee P, Canale V, et al
    Autoimmune susceptibility gene PTPN2 is required for clearance of adherent-invasive Escherichia coli by integrating bacterial uptake and lysosomal defence.
    Gut. 2022;71:89-99.
    PubMed     Abstract available

  20. MAO R, Doyon G, Gordon IO, Li J, et al
    Activated intestinal muscle cells promote preadipocyte migration: a novel mechanism for creeping fat formation in Crohn's disease.
    Gut. 2022;71:55-67.
    PubMed     Abstract available

  21. JONGSMA MME, Aardoom MA, Cozijnsen MA, van Pieterson M, et al
    First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn's disease: an open-label multicentre randomised controlled trial.
    Gut. 2022;71:34-42.
    PubMed     Abstract available

    December 2021
  22. BURR NE, Gracie DJ, Black CJ, Ford AC, et al
    Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis.
    Gut. 2021 Dec 22. pii: gutjnl-2021-326390. doi: 10.1136/gutjnl-2021-326390.
    PubMed     Abstract available

  23. WELLENS J, Edmans M, Obolski U, McGregor CG, et al
    Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease.
    Gut. 2021 Dec 15. pii: gutjnl-2021-326312. doi: 10.1136/gutjnl-2021-326312.

  24. LEPPKES M, Lindemann A, Gosswein S, Paulus S, et al
    Neutrophils prevent rectal bleeding in ulcerative colitis by peptidyl-arginine deiminase-4-dependent immunothrombosis.
    Gut. 2021 Dec 3. pii: gutjnl-2021-324725. doi: 10.1136/gutjnl-2021-324725.
    PubMed     Abstract available

  25. MCGREGOR CG, Adams A, Sadler R, Arancibia-Carcamo CV, et al
    Maintenance therapy with infliximab or vedolizumab in IBD is not associated with increased SARS-CoV-2 seroprevalence: UK experience in the 2020 pandemic.
    Gut. 2021;70:2398-2400.

  26. WELLENS J, Sabino J, Vermeire S
    PPIs and anti-TNF in patients with IBD: a forbidden combination?
    Gut. 2021;70:2397-2398.

  27. NA YR, Jung D, Stakenborg M, Jang H, et al
    Prostaglandin E2 receptor PTGER4-expressing macrophages promote intestinal epithelial barrier regeneration upon inflammation.
    Gut. 2021;70:2249-2260.
    PubMed     Abstract available

    November 2021
  28. SHIRE ZJ, Reicherz F, Lawrence S, Sudan H, et al
    Antibody response to the BNT162b2 SARS-CoV-2 vaccine in paediatric patients with inflammatory bowel disease treated with anti-TNF therapy.
    Gut. 2021 Nov 23. pii: gutjnl-2021-326196. doi: 10.1136/gutjnl-2021-326196.

  29. CROUWEL F, Buiter HJC, de Boer NKH
    There is still a place for optimised thiopurine therapy in IBD.
    Gut. 2021;70:2207.

    October 2021
  30. ODUFALU FD, Long M, Lin K, Mahadevan U, et al
    Exposure to corticosteroids in pregnancy is associated with adverse perinatal outcomes among infants of mothers with inflammatory bowel disease: results from the PIANO registry.
    Gut. 2021 Oct 22. pii: gutjnl-2021-325317. doi: 10.1136/gutjnl-2021-325317.
    PubMed     Abstract available

  31. ATTAUABI M, Seidelin J, Burisch J
    Association between 5-aminosalicylates in patients with IBD and risk of severe COVID-19: an artefactual result of research methodology?
    Gut. 2021;70:2020-2022.

  32. KENNEDY NA, Lin S, Goodhand JR, Chanchlani N, et al
    Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD.
    Gut. 2021;70:1884-1893.
    PubMed     Abstract available

  33. JUKIC A, Bakiri L, Wagner EF, Tilg H, et al
    Calprotectin: from biomarker to biological function.
    Gut. 2021;70:1978-1988.
    PubMed     Abstract available

    September 2021
  34. KHAN N, Mahmud N, Trivedi C, Reinisch W, et al
    Risk factors for SARS-CoV-2 infection and course of COVID-19 disease in patients with IBD in the Veterans Affair Healthcare System.
    Gut. 2021;70:1657-1664.
    PubMed     Abstract available

  35. ADEGBOLA SO, Dibley L, Sahnan K, Wade T, et al
    Development and initial psychometric validation of a patient-reported outcome measure for Crohn's perianal fistula: the Crohn's Anal Fistula Quality of Life (CAF-QoL) scale.
    Gut. 2021;70:1649-1656.
    PubMed     Abstract available

  36. KANDIAH K, Subramaniam S, Thayalasekaran S, Chedgy FJ, et al
    Multicentre randomised controlled trial on virtual chromoendoscopy in the detection of neoplasia during colitis surveillance high-definition colonoscopy (the VIRTUOSO trial).
    Gut. 2021;70:1684-1690.
    PubMed     Abstract available

    August 2021
  37. GORELIK Y, Freilich S, Gerassy-Vainberg S, Pressman S, et al
    Antibiotic use differentially affects the risk of anti-drug antibody formation during anti-TNFalpha therapy in inflammatory bowel disease patients: a report from the epi-IIRN.
    Gut. 2021 Aug 3. pii: gutjnl-2021-325185. doi: 10.1136/gutjnl-2021-325185.
    PubMed     Abstract available

    July 2021
  38. VERSTOCKT B, Boets L, Sabino J, Vermeire S, et al
    Thiopurine monotherapy has a limited place in treatment of patients with mild-to-moderate Crohn's disease.
    Gut. 2021;70:1416-1418.

  39. CARON B, Sandborn WJ, Schreiber S, Panaccione R, et al
    Drug development for ulcerative proctitis: current concepts.
    Gut. 2021;70:1203-1209.

    June 2021
  40. HANSEN R, Meade S, Beattie RM, Auth MK, et al
    Adaptations to the current ECCO/ESPGHAN guidelines on the management of paediatric acute severe colitis in the context of the COVID-19 pandemic: a RAND appropriateness panel.
    Gut. 2021;70:1044-1052.
    PubMed     Abstract available

  41. AGRAWAL M, Corn G, Shrestha S, Nielsen NM, et al
    Inflammatory bowel diseases among first-generation and second-generation immigrants in Denmark: a population-based cohort study.
    Gut. 2021;70:1037-1043.
    PubMed     Abstract available

    May 2021
  42. CURTIUS K, Kabir M, Al Bakir I, Choi CHR, et al
    Multicentre derivation and validation of a colitis-associated colorectal cancer risk prediction web tool.
    Gut. 2021 May 14. pii: gutjnl-2020-323546. doi: 10.1136/gutjnl-2020-323546.
    PubMed     Abstract available

  43. KENNEDY NA, Goodhand JR, Bewshea C, Nice R, et al
    Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab.
    Gut. 2021;70:865-875.
    PubMed     Abstract available

  44. AXELRAD JE, Olen O, Sachs MC, Erichsen R, et al
    Reply: Survival in Crohn's disease-associated small bowel adenocarcinoma.
    Gut. 2021;70:998.

  45. GIUFFRIDA P, Vanoli A, Di Sabatino A
    Survival in Crohn's disease-associated small bowel adenocarcinoma.
    Gut. 2021;70:997-998.

    April 2021
  46. BOLTE LA, Vich Vila A, Imhann F, Collij V, et al
    Long-term dietary patterns are associated with pro-inflammatory and anti-inflammatory features of the gut microbiome.
    Gut. 2021 Apr 2. pii: gutjnl-2020-322670. doi: 10.1136/gutjnl-2020-322670.
    PubMed     Abstract available

  47. Correction: British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.
    Gut. 2021;70:1.

  48. LEES CW, Irving PM, Beaugerie L
    COVID-19 and IBD drugs: should we change anything at the moment?
    Gut. 2021;70:632-634.

  49. SIEGEL CA, Melmed GY, McGovern DP, Rai V, et al
    SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting.
    Gut. 2021;70:635-640.

  50. UNGARO RC, Brenner EJ, Gearry RB, Kaplan GG, et al
    Effect of IBD medications on COVID-19 outcomes: results from an international registry.
    Gut. 2021;70:725-732.
    PubMed     Abstract available

  51. ZHAO R, Wan QY, Wu Y, Wang Y, et al
    Crohn's disease instead of UC might increase the risk of small bowel cancer.
    Gut. 2021;70:809-810.

  52. GREUTER T, Rieder F, Kucharzik T, Peyrin-Biroulet L, et al
    Emerging treatment options for extraintestinal manifestations in IBD.
    Gut. 2021;70:796-802.
    PubMed     Abstract available

    March 2021
  53. ASHTON JJ, Ennis S, Beattie RM
    Infliximab at diagnosis: moving towards personalisation in paediatric inflammatory bowel disease.
    Gut. 2021 Mar 15. pii: gutjnl-2021-324214. doi: 10.1136/gutjnl-2021-324214.

  54. JUZNIC L, Peuker K, Strigli A, Brosch M, et al
    SETDB1 is required for intestinal epithelial differentiation and the prevention of intestinal inflammation.
    Gut. 2021;70:485-498.
    PubMed     Abstract available

    February 2021
  55. HU S, Vich Vila A, Gacesa R, Collij V, et al
    Whole exome sequencing analyses reveal gene-microbiota interactions in the context of IBD.
    Gut. 2021;70:285-296.
    PubMed     Abstract available

  56. TAKENAKA K, Kimura M, Ohtsuka K
    Colonic strictures mimicking Crohn's disease.
    Gut. 2021;70:233-387.

    January 2021
  57. D'HAENS GR, van Deventer S
    25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the future.
    Gut. 2021 Jan 11. pii: gutjnl-2019-320022. doi: 10.1136/gutjnl-2019-320022.
    PubMed     Abstract available

    December 2020
  58. LU TX, Dapas M, Lin E, Peters T, et al
    The influence of proton pump inhibitor therapy on the outcome of infliximab therapy in inflammatory bowel disease: a patient-level meta-analysis of randomised controlled studies.
    Gut. 2020 Dec 17. pii: gutjnl-2020-321609. doi: 10.1136/gutjnl-2020-321609.
    PubMed     Abstract available

  59. HE X, Gao J, Peng L, Hu T, et al
    Bacterial O-GlcNAcase genes abundance decreases in ulcerative colitis patients and its administration ameliorates colitis in mice.
    Gut. 2020 Dec 12. pii: gutjnl-2020-322468. doi: 10.1136/gutjnl-2020-322468.
    PubMed     Abstract available

  60. HAIFER C, Saikal A, Paramsothy R, Kaakoush NO, et al
    Response to faecal microbiota transplantation in ulcerative colitis is not sustained long term following induction therapy.
    Gut. 2020 Dec 10. pii: gutjnl-2020-323581. doi: 10.1136/gutjnl-2020-323581.

  61. PAONE P, Cani PD
    Mucus barrier, mucins and gut microbiota: the expected slimy partners?
    Gut. 2020;69:2232-2243.
    PubMed     Abstract available

    November 2020
  62. DERKINDEREN P, Noble W, Neunlist M, Rolli-Derkinderen M, et al
    Upregulation of enteric alpha-synuclein as a possible link between inflammatory bowel disease and Parkinson's disease.
    Gut. 2020 Nov 17. pii: gutjnl-2020-323482. doi: 10.1136/gutjnl-2020-323482.

  63. KHALOIAN S, Rath E, Hammoudi N, Gleisinger E, et al
    Mitochondrial impairment drives intestinal stem cell transition into dysfunctional Paneth cells predicting Crohn's disease recurrence.
    Gut. 2020;69:1939-1951.
    PubMed     Abstract available

    October 2020
  64. BLACKWELL J, Saxena S, Petersen I, Hotopf M, et al
    Depression in individuals who subsequently develop inflammatory bowel disease: a population-based nested case-control study.
    Gut. 2020 Oct 27. pii: gutjnl-2020-322308. doi: 10.1136/gutjnl-2020-322308.
    PubMed     Abstract available

  65. LEE HS, Lobbestael E, Vermeire S, Sabino J, et al
    Inflammatory bowel disease and Parkinson's disease: common pathophysiological links.
    Gut. 2020 Oct 16. pii: gutjnl-2020-322429. doi: 10.1136/gutjnl-2020-322429.
    PubMed     Abstract available

  66. KANIS SL, Modderman S, Escher JC, Erler N, et al
    Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life.
    Gut. 2020 Oct 12. pii: gutjnl-2019-319129. doi: 10.1136/gutjnl-2019-319129.
    PubMed     Abstract available

  67. ASCHENBRENNER D, Quaranta M, Banerjee S, Ilott N, et al
    Deconvolution of monocyte responses in inflammatory bowel disease reveals an IL-1 cytokine network that regulates IL-23 in genetic and acquired IL-10 resistance.
    Gut. 2020 Oct 9. pii: gutjnl-2020-321731. doi: 10.1136/gutjnl-2020-321731.
    PubMed     Abstract available

  68. DIN S, Kent A, Pollok RC, Meade S, et al
    Adaptations to the British Society of Gastroenterology guidelines on the management of acute severe UC in the context of the COVID-19 pandemic: a RAND appropriateness panel.
    Gut. 2020;69:1769-1777.
    PubMed     Abstract available

  69. STOURNARAS E, Qian W, Pappas A, Hong YY, et al
    Thiopurine monotherapy is effective in ulcerative colitis but significantly less so in Crohn's disease: long-term outcomes for 11 928 patients in the UK inflammatory bowel disease bioresource.
    Gut. 2020 Oct 1. pii: gutjnl-2019-320185. doi: 10.1136/gutjnl-2019-320185.
    PubMed     Abstract available

  70. JIJON H, Ueno A, Sharifi N, Leung Y, et al
    Elevated interferon-gamma levels during pregnancy are associated with adverse maternofetal outcomes in IBD.
    Gut. 2020;69:1895-1897.

    September 2020
  71. BEELEN EMJ, van der Woude CJ, de Vries AC
    Intestinal resection rates in Crohn's disease decline across two different epidemiological areas: a consistent observation not merely due to introduction of anti-TNFalpha.
    Gut. 2020;69:1.

  72. KHALILI H, Hakansson N, Chan SS, Chen Y, et al
    Adherence to a Mediterranean diet is associated with a lower risk of later-onset Crohn's disease: results from two large prospective cohort studies.
    Gut. 2020;69:1637-1644.
    PubMed     Abstract available

    August 2020
  73. EFFENBERGER M, Grabherr F, Mayr L, Schwaerzler J, et al
    Faecal calprotectin indicates intestinal inflammation in COVID-19.
    Gut. 2020;69:1543-1544.

  74. SEYED TABIB NS, Madgwick M, Sudhakar P, Verstockt B, et al
    Big data in IBD: big progress for clinical practice.
    Gut. 2020;69:1520-1532.
    PubMed     Abstract available

    July 2020
  75. GOTTLIEB K, Daperno M, Usiskin K, Sands BE, et al
    Endoscopy and central reading in inflammatory bowel disease clinical trials: achievements, challenges and future developments.
    Gut. 2020 Jul 22. pii: gutjnl-2020-320690. doi: 10.1136/gutjnl-2020-320690.
    PubMed     Abstract available

  76. TURSI A, Angarano G, Monno L, Saracino A, et al
    COVID-19 infection in Crohn's disease under treatment with adalimumab.
    Gut. 2020;69:1364-1365.

  77. BEZZIO C, Saibeni S, Variola A, Allocca M, et al
    Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study.
    Gut. 2020;69:1213-1217.
    PubMed     Abstract available

    COVID-19 and immunomodulation in IBD.
    Gut. 2020;69:1335-1342.
    PubMed     Abstract available

  79. PAPAMICHAEL K, Cheifetz AS, Irving PM
    New role for azathioprine in case of switching anti-TNFs in IBD.
    Gut. 2020;69:1165-1167.

  80. ZUO T, Ng SC
    Authors response: giant oversights in the human gut virome.
    Gut. 2020;69:1358.

  81. SUTTON TDS, Clooney AG, Hill C
    Giant oversights in the human gut virome.
    Gut. 2020;69:1357-1358.

  82. DANESE S, Schabel E, Ainsworth MA, Peyrin-Biroulet L, et al
    Challenges and opportunities for IBD drug development: from early stage to regulatory approval.
    Gut. 2020;69:1157-1161.

  83. ROBLIN X, Williet N, Boschetti G, Phelip JM, et al
    Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial.
    Gut. 2020;69:1206-1212.
    PubMed     Abstract available

    June 2020
  84. ZHANG B, Wang HE, Bai YM, Tsai SJ, et al
    Inflammatory bowel disease is associated with higher dementia risk: a nationwide longitudinal study.
    Gut. 2020 Jun 23. pii: gutjnl-2020-320789. doi: 10.1136/gutjnl-2020-320789.
    PubMed     Abstract available

  85. BEZZIO C, Manes G, Bini F, Pellegrini L, et al
    Infliximab for severe ulcerative colitis and subsequent SARS-CoV-2 pneumonia: a stone for two birds.
    Gut. 2020 Jun 17. pii: gutjnl-2020-321760. doi: 10.1136/gutjnl-2020-321760.

  86. CLOONEY AG, Eckenberger J, Laserna-Mendieta E, Sexton KA, et al
    Ranking microbiome variance in inflammatory bowel disease: a large longitudinal intercontinental study.
    Gut. 2020 Jun 14. pii: gutjnl-2020-321106. doi: 10.1136/gutjnl-2020-321106.
    PubMed     Abstract available

  87. KOELINK PJ, Bloemendaal FM, Li B, Westera L, et al
    Anti-TNF therapy in IBD exerts its therapeutic effect through macrophage IL-10 signalling.
    Gut. 2020;69:1053-1063.
    PubMed     Abstract available

    May 2020
  88. AXELRAD JE, Olen O, Sachs MC, Erichsen R, et al
    Inflammatory bowel disease and risk of small bowel cancer: a binational population-based cohort study from Denmark and Sweden.
    Gut. 2020 May 30. pii: gutjnl-2020-320945. doi: 10.1136/gutjnl-2020-320945.
    PubMed     Abstract available

  89. QI X, Liu Y, Wang J, Fallowfield J, et al
    Clinical course and risk factors for mortality of COVID-19 patients with pre-existing cirrhosis: a multicentre cohort study.
    Gut. 2020 May 20. pii: gutjnl-2020-321666. doi: 10.1136/gutjnl-2020-321666.

  90. CLOUGH JN, Omer OS, Tasker S, Lord GM, et al
    Regulatory T-cell therapy in Crohn's disease: challenges and advances.
    Gut. 2020;69:942-952.
    PubMed     Abstract available

  91. KIRCHGESNER J, Nyboe Andersen N, Carrat F, Jess T, et al
    Risk of acute arterial events associated with treatment of inflammatory bowel diseases: nationwide French cohort study.
    Gut. 2020;69:852-858.
    PubMed     Abstract available

  92. GARG M, Royce SG, Tikellis C, Shallue C, et al
    Imbalance of the renin-angiotensin system may contribute to inflammation and fibrosis in IBD: a novel therapeutic target?
    Gut. 2020;69:841-851.
    PubMed     Abstract available

    April 2020
  93. KENNEDY NA, Jones GR, Lamb CA, Appleby R, et al
    British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic.
    Gut. 2020 Apr 17. pii: gutjnl-2020-321244. doi: 10.1136/gutjnl-2020-321244.
    PubMed     Abstract available

  94. MAZZA S, Sorce A, Peyvandi F, Vecchi M, et al
    A fatal case of COVID-19 pneumonia occurring in a patient with severe acute ulcerative colitis.
    Gut. 2020 Apr 3. pii: gutjnl-2020-321183. doi: 10.1136/gutjnl-2020-321183.

  95. FAIRBRASS KM, Hoshen D, Gracie DJ, Ford AC, et al
    Effect of ACE inhibitors and angiotensin II receptor blockers on disease outcomes in inflammatory bowel disease.
    Gut. 2020 Apr 2. pii: gutjnl-2020-321186. doi: 10.1136/gutjnl-2020-321186.

  96. PANACCIONE R, Colombel JF, Travis SPL, Bossuyt P, et al
    Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial.
    Gut. 2020;69:658-664.
    PubMed     Abstract available

  97. BOSSUYT P, Vermeire S, Bisschops R
    Scoring endoscopic disease activity in IBD: artificial intelligence sees more and better than we do.
    Gut. 2020;69:788-789.

    March 2020
  98. VALLERAND I, Frolkis AD, Patten S, Kaplan GG, et al
    Changing trends in coding for depression among the UK IBD population: reply from authors.
    Gut. 2020;69:607.

  99. POWELL N, Pantazi E, Pavlidis P, Tsakmaki A, et al
    Interleukin-22 orchestrates a pathological endoplasmic reticulum stress response transcriptional programme in colonic epithelial cells.
    Gut. 2020;69:578-590.
    PubMed     Abstract available

  100. VAN DER GIESSEN J, Binyamin D, Belogolovski A, Frishman S, et al
    Modulation of cytokine patterns and microbiome during pregnancy in IBD.
    Gut. 2020;69:473-486.
    PubMed     Abstract available

  101. SOKOL H, Brot L, Stefanescu C, Auzolle C, et al
    Prominence of ileal mucosa-associated microbiota to predict postoperative endoscopic recurrence in Crohn's disease.
    Gut. 2020;69:462-472.
    PubMed     Abstract available

  102. OLEN O, Askling J, Sachs MC, Neovius M, et al
    Mortality in adult-onset and elderly-onset IBD: a nationwide register-based cohort study 1964-2014.
    Gut. 2020;69:453-461.
    PubMed     Abstract available

    February 2020
  103. MURTHY SK, Begum J, Benchimol EI, Bernstein CN, et al
    Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study.
    Gut. 2020;69:274-282.
    PubMed     Abstract available

  104. SUN R, Hedl M, Abraham C
    IL23 group> IL23R recycling and amplifies innate receptor-induced signalling and cytokines in human macrophages, and the IBD-protective IL23R R381Q variant modulates these outcomes.
    Gut. 2020;69:264-273.
    PubMed     Abstract available

  105. SCHLEIER L, Wiendl M, Heidbreder K, Binder MT, et al
    Non-classical monocyte homing to the gut via alpha4beta7 integrin mediates macrophage-dependent intestinal wound healing.
    Gut. 2020;69:252-263.
    PubMed     Abstract available

    January 2020
  106. DOLMAN GE, Kennedy PTF
    Hepatitis B reactivation: reducing the risk in patients with inflammatory bowel disease.
    Gut. 2020 Jan 30. pii: gutjnl-2019-319480. doi: 10.1136/gutjnl-2019-319480.

  107. BOSSUYT P, Nakase H, Vermeire S, de Hertogh G, et al
    Automatic, computer-aided determination of endoscopic and histological inflammation in patients with mild to moderate ulcerative colitis based on red density.
    Gut. 2020 Jan 8. pii: gutjnl-2019-320056. doi: 10.1136/gutjnl-2019-320056.
    PubMed     Abstract available

  108. NG SC, Kamm MA, Yeoh YK, Chan PKS, et al
    Scientific frontiers in faecal microbiota transplantation: joint document of Asia-Pacific Association of Gastroenterology (APAGE) and Asia-Pacific Society for Digestive Endoscopy (APSDE).
    Gut. 2020;69:83-91.
    PubMed     Abstract available

  109. TORRES J, Hu J, Seki A, Eisele C, et al
    Infants born to mothers with IBD present with altered gut microbiome that transfers abnormalities of the adaptive immune system to germ-free mice.
    Gut. 2020;69:42-51.
    PubMed     Abstract available

  110. TURNER D, Griffiths AM, Wilson D, Mould DR, et al
    Designing clinical trials in paediatric inflammatory bowel diseases: a PIBDnet commentary.
    Gut. 2020;69:32-41.
    PubMed     Abstract available

  111. WAN QY, Zhao R, Wu XT
    Older patients with IBD might have higher risk of Parkinson's disease.
    Gut. 2020;69:193-194.

  112. TULKENS J, Vergauwen G, Van Deun J, Geeurickx E, et al
    Increased levels of systemic LPS-positive bacterial extracellular vesicles in patients with intestinal barrier dysfunction.
    Gut. 2020;69:191-193.

    December 2019
  113. MAASER C, Petersen F, Helwig U, Fischer I, et al
    Intestinal ultrasound for monitoring therapeutic response in patients with ulcerative colitis: results from the TRUST&UC study.
    Gut. 2019 Dec 20. pii: gutjnl-2019-319451. doi: 10.1136/gutjnl-2019-319451.
    PubMed     Abstract available

  114. CHA JM, Park SH, Rhee KH, Hong SN, et al
    Long-term prognosis of ulcerative colitis and its temporal changes between 1986 and 2015 in a population-based cohort in the Songpa-Kangdong district of Seoul, Korea.
    Gut. 2019 Dec 10. pii: gutjnl-2019-319699. doi: 10.1136/gutjnl-2019-319699.
    PubMed     Abstract available

  115. DE BARRIOS O, Sanchez-Moral L, Cortes M, Ninfali C, et al
    ZEB1 promotes inflammation and progression towards inflammation-driven carcinoma through repression of the DNA repair glycosylase MPG in epithelial cells.
    Gut. 2019;68:2129-2141.
    PubMed     Abstract available

  116. LIMKETKAI BN, Shah SC, Hirano I, Bellaguarda E, et al
    Epidemiology and implications of concurrent diagnosis of eosinophilic oesophagitis and IBD based on a prospective population-based analysis.
    Gut. 2019;68:2152-2160.
    PubMed     Abstract available

    November 2019
  117. JONES GR, Lyons M, Plevris N, Jenkinson PW, et al
    IBD prevalence in Lothian, Scotland, derived by capture-recapture methodology.
    Gut. 2019;68:1953-1960.
    PubMed     Abstract available

  118. ALLEZ M, Auzolle C, Ngollo M, Bottois H, et al
    T cell clonal expansions in ileal Crohn's disease are associated with smoking behaviour and postoperative recurrence.
    Gut. 2019;68:1961-1970.
    PubMed     Abstract available

  119. PAI RK, Khanna R, D'Haens GR, Sandborn WJ, et al
    Definitions of response and remission for the Robarts Histopathology Index.
    Gut. 2019;68:2101-2102.

    October 2019
  120. DE GROOF EJ, Stevens TW, Eshuis EJ, Gardenbroek TJ, et al
    Cost-effectiveness of laparoscopic ileocaecal resection versus infliximab treatment of terminal ileitis in Crohn's disease: the LIR!C Trial.
    Gut. 2019;68:1774-1780.
    PubMed     Abstract available

    September 2019
  121. LAMB CA, Kennedy NA, Raine T, Hendy PA, et al
    British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.
    Gut. 2019 Sep 27. pii: gutjnl-2019-318484. doi: 10.1136/gutjnl-2019-318484.
    PubMed     Abstract available

  122. PARKES M
    IBD BioResource: an open-access platform of 25 000 patients to accelerate research in Crohn's and Colitis.
    Gut. 2019;68:1537-1540.

    April 2019
  123. LEMOINNE S, Kemgang A, Ben Belkacem K, Straube M, et al
    Fungi participate in the dysbiosis of gut microbiota in patients with primary sclerosing cholangitis.
    Gut. 2019 Apr 19. pii: gutjnl-2018-317791. doi: 10.1136/gutjnl-2018-317791.
    PubMed     Abstract available

    December 2018
  124. STJARNGRIM J, Ekbom A, Hammar U, Hultcrantz R, et al
    Rates and characteristics of postcolonoscopy colorectal cancer in the Swedish IBD population: what are the differences from a non-IBD population?
    Gut. 2018 Dec 15. pii: gutjnl-2018-316651. doi: 10.1136/gutjnl-2018-316651.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.